Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH, PCORI Seek Applications for Falls Prevention Clinical Trial

Published: Friday, July 19, 2013
Last Updated: Thursday, July 18, 2013
Bookmark and Share
Research to focus on methods to prevent serious injuries in older people.

The National Institute on Aging (NIA) is seeking applications from researchers for a clinical trial to prevent serious injuries resulting from falls in older people.

The request, part of an initiative by the new Falls Injuries Prevention Partnership between NIA and the Patient Centered Outcomes Research Institute (PCORI), represents a unique collaboration joining scientists with clinicians and patients in pursuit of an effective strategy.

PCORI will commit up to $30 million to the effort, and NIA will administer the project, including the application process and peer review.

NIA is part of the National Institutes of Health, PCORI is authorized by Congress to fund research to provide information about the best available evidence to help patients and their health care providers make more informed decisions.

“Serious injuries from falls, such as broken bones or traumatic brain injury, are a major reason for the loss of independence among older people,” said NIA Director Richard J. Hodes, M.D.

Hodes continued, “This is a significant public health problem, greatly affecting older adults and their families - as well as the health care system. The clinical trial envisioned here seeks to test a comprehensive and practical approach that can make real progress in reducing these injuries.”

Falls resulting in serious injury depend on several factors, including an individual’s risk of falling, his or her physical and cognitive condition, the surrounding environment, and the ability to reduce risks.

The formal Request for Applications (RFA) asks for proposals that address these factors together, in a multifactorial approach.

Data are limited on reducing serious injuries through the use of multifactorial falls prevention strategies, with some trials finding favorable results.

More recent studies have aimed at decreasing serious injuries, beyond a focus on simply preventing falls. However, to date, definitive large-scale studies that can be broadly applied by clinicians and accepted by older adults have not been conducted.

Additionally, there is little evidence about the effectiveness of such strategies on other outcomes important to patients.

The RFA issued by the NIA outlines the rationale for the trial, along with the required elements of any proposal. A key element is the active involvement in the design and conduct of the study by older patients, family caregivers, health care professionals, and other stakeholders.

The ultimate goal of bringing together these interests is to help ensure that the strategy can be reliably replicated and used in at least one health care setting.

The strategy, NIA’s request says, should be designed to identify individuals at high risk for falling, assess them to define their specific risk factors, select interventions to address these factors, and monitor progress toward risk factor reduction.

“PCORI’s goal is to develop evidence and provide information on the best available evidence to help patients and their health care providers make better informed decisions,” said PCORI Executive Director Joe Selby, M.D., M.P.H.

Selby continued, “Finding a practical approach to preventing injuries from falls is one area where we think we can have a major impact, especially if we have active input from patients and other stakeholders from the very beginning of a study.”

Anyone interested in submitting a proposal is invited to consult the full RFA regarding submission policies, instructions, and requirements.

The RFA is available at http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-14-009.html. Proposals are due on Nov. 13, 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Saturday, July 25, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Tuesday, July 21, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Thursday, July 02, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder
Clinical trial will evaluate the safety and effectiveness of gabapentin enacarbil in treating alcohol use disorder.
Friday, June 26, 2015
Study of Ebola Survivors Opens in Liberia
Trial to examine long-term health effects of Ebola virus disease.
Friday, June 19, 2015
NIH Names Walter J. Koroshetz, M.D. Director of the NINDS
Dr. Collins recognized Dr. Koroshetz’ role in the creation of the StrokeNet.
Saturday, June 13, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
Two Treatments Yield Similar Results for Children After Cardiac Arrest
NIH-funded research finds therapeutic hypothermia no more effective than normal temperature control.
Friday, May 08, 2015
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!